BidaskClub lowered shares of Sientra (NASDAQ:SIEN) from a strong-buy rating to a buy rating in a research note issued to investors on Tuesday, September 18th.

Other equities research analysts also recently issued reports about the stock. Craig Hallum started coverage on shares of Sientra in a research note on Monday, June 4th. They issued a buy rating and a $23.00 target price for the company. Dougherty & Co initiated coverage on shares of Sientra in a report on Thursday, August 30th. They issued a buy rating and a $31.00 price target on the stock. Stephens reissued a buy rating and issued a $30.00 price target on shares of Sientra in a report on Thursday, August 9th. Stifel Nicolaus increased their price target on shares of Sientra from $21.00 to $25.00 and gave the company a buy rating in a report on Wednesday, August 8th. Finally, Canaccord Genuity raised their target price on shares of Sientra from $19.00 to $25.00 and gave the stock a buy rating in a report on Wednesday, August 8th. One analyst has rated the stock with a sell rating, ten have issued a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of Buy and a consensus price target of $22.50.

Shares of SIEN traded up $0.89 during trading hours on Tuesday, reaching $21.46. The stock had a trading volume of 343,696 shares, compared to its average volume of 422,977. The stock has a market cap of $678.85 million, a P/E ratio of -7.61 and a beta of -0.78. The company has a quick ratio of 2.63, a current ratio of 3.06 and a debt-to-equity ratio of 0.27. Sientra has a 52 week low of $8.79 and a 52 week high of $26.79.

Sientra (NASDAQ:SIEN) last released its earnings results on Tuesday, August 7th. The medical instruments supplier reported ($0.73) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.69) by ($0.04). Sientra had a negative return on equity of 151.47% and a negative net margin of 131.16%. The firm had revenue of $17.55 million for the quarter, compared to the consensus estimate of $15.30 million. On average, equities research analysts expect that Sientra will post -2.93 earnings per share for the current fiscal year.

In other Sientra news, CEO Jeffrey M. Nugent sold 1,852 shares of the firm’s stock in a transaction that occurred on Friday, August 31st. The shares were sold at an average price of $24.90, for a total value of $46,114.80. Following the sale, the chief executive officer now owns 297,999 shares in the company, valued at $7,420,175.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 31.00% of the company’s stock.

A number of institutional investors have recently modified their holdings of the business. Bank of America Corp DE boosted its position in Sientra by 16.2% in the second quarter. Bank of America Corp DE now owns 26,638 shares of the medical instruments supplier’s stock valued at $519,000 after buying an additional 3,718 shares in the last quarter. Rhumbline Advisers lifted its holdings in shares of Sientra by 55.6% during the second quarter. Rhumbline Advisers now owns 21,621 shares of the medical instruments supplier’s stock worth $422,000 after purchasing an additional 7,725 shares during the period. Metropolitan Life Insurance Co. NY acquired a new position in shares of Sientra during the second quarter worth $160,000. BlackRock Inc. lifted its holdings in shares of Sientra by 1.2% during the first quarter. BlackRock Inc. now owns 767,308 shares of the medical instruments supplier’s stock worth $7,411,000 after purchasing an additional 8,796 shares during the period. Finally, Commonwealth Equity Services LLC acquired a new position in shares of Sientra during the second quarter worth $210,000. Hedge funds and other institutional investors own 89.22% of the company’s stock.

About Sientra

Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.

Featured Article: What is insider trading?

Analyst Recommendations for Sientra (NASDAQ:SIEN)

Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.